Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 278 No 7440 p211
24 February 2007

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Consultation starts on contract application fees

Charges of up to £3,000 could be levied on contractors applying to provide pharmaceutical services in England.

A Government consultation published last week proposes amendments to the 2005 Regulations to implement the provisions of the Health Act 2006. These are to enable “reasonable charges” to be introduced for applications concerning inclusion on an NHS primary care trust’s list.

The fees are designed to defray the costs of assessing each application and to deter speculative and time-wasting applications, the DoH says. “There is, even within the reformed regime now in place, no deterrent to a business which wishes to enter speculative bids to open a new chemist, either as a fishing expedition in the hope that one or more may be granted or to have the effect of blocking other applicants being considered.”

The fees proposed vary from £150 for a minor relocation or change of ownership to £3,000 for a duplicate application submitted within 180 days of the failure of a previous application. The consultation adds: “The DoH proposes that the fee shall not be refundable whether the application is successful or not because a PCT will incur costs in all cases in determining an application, whatever its outcome.”

When the Government originally suggested introducing these changes, the Pharmaceutical Services Negotiating Committee argued that fees should not be payable for pharmacy relocations or changes to ownership and that all fees should be refunded to successful applicants.

Steve Lutener, head of regulation at the PSNC, told The Journal this week that the committee would be considering carefully whether its position on refundability had changed.

The consultation document is available from the DoH website. Comments can be sent to Gillian Farnfield by 11 May (e-mail gillian.farnfield@dh.gsi.gov.uk).

Back to Top


©The Pharmaceutical Journal